Intravenous Ketorolac Substantially Reduces Opioid Use and Length of Stay After Lumbar Fusion: A Randomized Controlled Trial.

この研究はインパクトが大きい可能性があると判断されました。 OEのAIによるハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文の影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することができ、読者は将来の診療を形成する可能性が最も高い論文に焦点を当てることができます。

研究概要

178 patients with conditions requiring lumbar fusion were randomized to receive either intravenous ketorolac (n=60), intravenous acetaminophen (n=58), or intravenous placebo (n=60). The primary outcome of interest was in-hospital opioid use up to 72 hours. Secondary outcomes included opioid-related adverse events, incidence of radiographic fusion, length of stay, worst, average, best, and current pain using the Brief Pain Inventory (BPI) scale, Oswestry Disability Index (ODI), Veteran's Rand 12-item Health Survey (VR-12) Physical Component Score (PCS), and the VR-12 Mental Component Score. All outcomes were assessed up to 72 hours post-surgery, whereas ODI and VR-12 scores were assessed at 3 months, 1, and 2 years. Overall, the results of the study revealed that patients receiving intravenous ketorolac had significantly lower opioid use and shorter hospital stays compared to the other groups, with no increase in adverse events or pseudarthrosis. The findings suggest that intravenous ketorolac is an effective component of enhanced recovery after surgery protocols for patients undergoing lumbar fusion.